Skip to content

13F-HR filed by Fairmount Funds Management LLC

Fairmount Funds Management LLC filed this 13F-HR for the quarter ended 2024-12-31, filed 2025-02-14, with 17 holding rows worth $1,005,884,370.

Accession
0001104659-25-014003
Filed
2025-02-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2024

A holdings report, 17 entries on the cover page, a total value of $1,005,884,370 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,005,884,370 with VALUE read as dollars as filed, 13F file number 028-19908. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
AXSOME THERAPEUTICS INC. COM05464T104Stock1,468,983$124,290,652dollars as filed
NUVALENT INC COM670703107Stock1,317,664$103,146,738dollars as filed
SPYRE THERAPEUTICS INC00773J202COM NEW4,018,101$93,541,391dollars as filed
APOGEE THERAPEUTICS INC COM03770N101Stock2,048,647$92,803,709dollars as filed
SCHOLAR ROCK HLDG CORP80706P103COM1,962,953$84,838,829dollars as filed
ENLIVEN THERAPEUTICS INC COM29337E102Stock3,202,798$72,062,955dollars as filed
VIRIDIAN THERAPEUTICS INC92790C104COM3,445,813$66,056,235dollars as filed
ORUKA THERAPEUTICS INC COM687604108Stock3,371,922$65,381,568dollars as filed
DIANTHUS THERAPEUTICS INC252828108COM2,700,691$58,875,064dollars as filed
COGENT BIOSCIENCES INC19240Q201COM6,225,641$48,560,000dollars as filed
KINIKSA PHARMACEUTICALS INTL P ORD SHS CL AG52694109Stock2,194,341$43,404,065dollars as filed
Day One Biopharmaceuticals Inc23954D109Common Stock3,103,448$39,320,686dollars as filed
ASTRIA THERAPEUTICS INC COM04635X102Stock3,554,129$31,773,913dollars as filed
ANAPTYSBIO INC032724106COM1,816,466$24,050,010dollars as filed
BICARA THERAPEUTICS INC055477103COM1,284,169$22,370,224dollars as filed
INHIBIKASE THERAPEUTICS INC45719W205COMMON STOCK6,125,000$19,906,250dollars as filed
ZENAS BIOPHARMA INC COM98937L105Stock1,892,806$15,502,081dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001104659-25-014003this filing2025-02-14acceptance time not in the bulk data set